Compare FTS & CNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTS | CNC |
|---|---|---|
| Founded | 1885 | 1984 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.5B | 32.9B |
| IPO Year | 2016 | 2001 |
| Metric | FTS | CNC |
|---|---|---|
| Price | $59.63 | $70.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 21 |
| Target Price | $56.00 | ★ $75.39 |
| AVG Volume (30 Days) | 905.4K | ★ 4.9M |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | ★ 3.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 5.15 |
| Revenue | N/A | ★ $194,777,000,000.00 |
| Revenue This Year | $11.18 | $13.55 |
| Revenue Next Year | $3.76 | N/A |
| P/E Ratio | $22.72 | ★ $13.61 |
| Revenue Growth | N/A | ★ 19.44 |
| 52 Week Low | $49.99 | $31.63 |
| 52 Week High | $61.71 | $78.08 |
| Indicator | FTS | CNC |
|---|---|---|
| Relative Strength Index (RSI) | 63.46 | 54.64 |
| Support Level | $54.52 | $63.74 |
| Resistance Level | $61.71 | $72.50 |
| Average True Range (ATR) | 0.87 | 3.52 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 54.41 | 46.11 |
Fortis owns and operates eight utility transmission and distribution subsidiaries in Canada and the United States, serving 3.5 million electricity and gas customers. The company has smaller stakes in electricity generation and several Caribbean utilities. Subsidiary ITC operates electric transmission in seven US states, with more than 16,000 miles of high-voltage transmission lines in operation.
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.